|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT03299829 |
|
Date of registration:
|
25/09/2017 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients
|
|
Scientific title:
|
A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients |
|
Date of first enrolment:
|
January 10, 2018 |
|
Target sample size:
|
48 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT03299829 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Taiwan
| | | | | | | |
|
Contacts
|
|
Name:
|
Chinchang Huange, Doctor |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Chang Gung Memorial Hospital |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Diagnosis of Wilson's disease.
- Male or female patients, aged 3 years to 75 years
Exclusion Criteria:
- Patients with comorbidity which is not related to Wilson's disease.
Age minimum:
3 Years
Age maximum:
75 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Trientine Treatment for Wilson's Disease
|
|
Intervention(s)
|
|
Drug: Trientine
|
|
Primary Outcome(s)
|
|
The improvement in liver function
[Time Frame: Up to 1 year]
|
|
Secondary Outcome(s)
|
|
The improvement in urine copper excretion
[Time Frame: Up to 1 year]
|
|
Secondary ID(s)
|
|
EB-TR-001
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|